REGULATORY

MHLW to Draw Up Guidelines on Registry Data Use for Submissions: Clinical Innovation Network Initiative

March 15, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Health, Labor and Welfare (MHLW) plans to draw up draft guidelines on the use of disease registry data for regulatory submissions in FY2019 and announce the finalized version in FY2020 at the earliest as part of the…

To read the full story

Centralized Support Unit Needed for “Clinical Innovation Network”: JPMA’s Teshirogi
April 8, 2016
Council on “Clinical Innovation Network” Holds 1st Meeting, 7 Working Groups to Design Registries
August 21, 2015

REGULATORY

LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
June 5, 2026
Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
June 5, 2026
Trazenta Generic Outlook Remains Clouded as Court Upholds Treatment-Method Patents
June 4, 2026
LDP Generic Caucus Wants Swift Disclosure of Company Indicator Ratings
June 4, 2026
LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…